Reading this on a mobile device? Try our optimized mobile version here: http://r.smartbrief.com/resp/dZufCfbwoceTeCsJkukF

November 14, 2012
Sign upForwardArchiveAdvertiseRead more at SmartBrief.com
News for nuclear medicine and molecular imaging professionals
 
The news summaries appearing in SNMMI SmartBrief are based on original information from multiple internet sources and are produced by SmartBrief, Inc., an independent e-mail newsletter publisher. The items below are not selected or reviewed by SNMMI prior to publication. Questions and comments may be directed to SmartBrief at snmmi@smartbrief.com.

  Top Story 
 
  • CMS posts specification sheets for stage 2 MU
    The specification sheets for the second stage of EHR meaningful use have been posted by CMS for eligible hospitals and professionals. The sheets are created to help them calculate the numerator and denominator for every MU objective and judge whether they qualify to be excluded from an objective. Health Data Management (11/12) LinkedInFacebookTwitterEmail this Story
  ADVERTISEMENT  
Nuclear Medicine Series
CriticalPoint is offering updated education and a way to earn ASRT
Cat A or ACPE CE
. 11 unique courses address fundamental skills while meeting the needs of Nuclear Pharmacists, Technicians and Nuclear Medicine Technologists. Register @ http://isotope.criticalpoint-lms.com - limited # get FREE TRAINING using code: NUCEDU
  Clinical News & Research 
  • Studies explore benefits of adding radiolabeled agents to treatments
    Three studies published in Cancer Biotherapy and Radiopharmaceuticals explored the potential of adding radiolabeled agents to protocols to improve the treatment of metastatic cancer. One study found that combining chemotherapy and radionuclides may improve efficacy and reduce toxicity in advanced forms of lymphoma and neuroendocrine tumors, while another study found that adding a radioimmunotherapeutic agent to treatment for non-Hodgkin lymphoma improved disease-free survival. A third study found that adding a lutetium-177 labeled peptide to the treatment protocol for advanced neuroendocrine cancer did not cause adverse effects and improved tumor management. ScienceDaily/News release (11/13) LinkedInFacebookTwitterEmail this Story
  Industry Report 
  • Epic Sciences raises $13M for CTCs blood test
    Epic Sciences has raised $13 million, which the company will use to advance its molecular diagnostics technology for detecting circulating tumor cells in the blood. The blood testing system, which the company says offers an alternative to standard biopsies, can be repeated to track disease progression and could also aid in the development of personalized treatments. MedCityNews.com (11/13) LinkedInFacebookTwitterEmail this Story
  News from the Field 
  Health Policy 
  • Hardship exemption deadline extended by CMS
    CMS has extended its deadline for filing hardship exemptions to avoid Medicare payment penalties next year. CMS-designated groups and qualified professionals can claim the exemption on the CMS website until Jan. 31, 2013. Physicians who do not meet e-prescribing requirements could lose 1.5% of their Medicare payment rates next year without the exemption. Modern Medicine/Medical Economics (11/12) LinkedInFacebookTwitterEmail this Story
  Advancing Health Care 
 
  • Brain collector seeks to untangle Alzheimer's disease
    Claude Wischik has collected the brains of more than 300 patients who died with Alzheimer's disease in an effort to determine what causes the disease. While the scientific and drug development communities pursue the theory that beta amyloid plaques are to blame, Wischik believes tau proteins drive the disease. The company he co-founded, TauRx Pharmaceuticals, is launching two clinical trials to test a drug that targets tau proteins. The Wall Street Journal (11/9) LinkedInFacebookTwitterEmail this Story
  ADVERTISEMENT  
  From SNMMI 
SNMMI  |  News  |  Meetings  |  Education  |  Publications  |  Membership

SNMMI on Facebook  |  SNMMI on LinkedIn  |  SNMMI on Twitter  |  SNMMI on YouTube

  SmartQuote 
The best way to find out if you can trust somebody is to trust them."
--Ernest Hemingway,
American author and journalist


LinkedInFacebookTwitterEmail this Story

 
 
Subscriber Tools
   
Print friendly format  | Web version  | Search past news  | Archive  | Privacy policy

Advertise
Account Director:   Meryl Harold   (202) 407-7828
 
Read more at SmartBrief.com
 
 
 Recent SNMMI SmartBrief Issues:   Lead Editor:   Melissa Turner
     
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
 
 
© 1999-2012 SmartBrief, Inc.®  Legal Information